.Attributes Medicine, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) treatment of individuals along with HER2+ sophisticated breast cancer and active or even stable human brain metastases revealed constant intracranial task and systemic efficacy of T-DXd.